Iovance Biotherapeutics (IOVA) Highlights Updated Clinical Data for Tumor Infiltrating Lymphocyte Therapy Lifileucel in Advanced Melanoma

Iovance Biotherapeutics (IOVA) Prices 16.935M Share Common Offering at $31/Sh

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) today announced the pricing of an underwritten public offering of 16,935,484 shares of its common stock at a public offering price of $31.00 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Iovance, are expected to be approximately $525 million. In... More

Pre-Open Stock Movers 05/28: (PHAS) (TGI) (DLTR) (TOL) (ALXN) (HTZ) (TWTR) (More...)

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) +54%; announced FDA authorization to proceed with VANGARD, a potentially pivotal clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS).

Triumph Group (NYSE: TGI) +24%; reported Q4 EPS of $0.69, $0.05 better than the analyst estimate of $0.64. Revenue for the quarter came in at $693.1 million versus the consensus estimate of $660.1 million.

Dollar Tree (NASDAQ:... More

Iovanace Biotherapeutics (IOVA) PT Raised to $50 at Stifel

Stifel analyst Benjamin Burnett raised the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $50.00 (from $48.00) while maintaining a Buy rating.... More

After-Hours Stock Movers 05/27: (PHAS) (SMTC) (TOL) Higher; (IOVA) (ARNA) (PLT) Lower (more...)

Today's After-Hours Stock Movers:

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) 74.4% HIGHER; announced FDA authorization to proceed with VANGARD, a potentially pivotal clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS).

Semtech (NASDAQ: SMTC) 13.6% HIGHER; reported Q1 EPS of $0.35, $0.03 better than the analyst estimate of $0.32. Revenue for the quarter came in at $132.7 million versus the consensus estimate of $129.28 million. Semtech sees Q2 2021 EPS of... More

Iovance Biotherapeutics (IOVA) Announces Proposed $500M Common Share Offering

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) today announced that it intends to offer and sell $500 million of its common stock, subject to market and other conditions, in an underwritten public offering. All of the shares in the offering are to be sold by Iovance.... More

Iovance Biotherapeutics (IOVA) Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced initial data from pivotal Cohort 4 and updated long-term data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma.

We are very pleased to announce our pivotal Cohort 4 early data from the C-144-01 clinical study in advanced melanoma today, said Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance Biotherapeutics. The data from the first 68 patients in Cohort 4, with a 32.4% overall response rate (ORR) at 5.3 months of median study... More